Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Supha PharmachemBOM:539561 56 PS Ratio is 0.04 as of Aug. 10, 2026, which is 85% below its 10-year median of 0.27. GuruFocus rates BOM:539561 with a GF Score™ of 56/100 and a GF Value™ of ₹1.52 (Possible Value Trap). The stock has 12 warning signs investors should review. Among 953 Drug Manufacturers companies, Supha Pharmachem ranks better than 99.27% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Supha Pharmachem's share price is ₹0.33.
Supha Pharmachem's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 was ₹8.33. Hence, Supha Pharmachem's PS Ratio for today is 0.04.
The historical rank and industry rank for Supha Pharmachem's PS Ratio or its related term are showing as below:
BOM:539561'
s PS Ratio Range Over the Past 10 Years
Min: 0.03 Med: 0.27 Max: 61.39
Current: 0.04
During the past 11 years, Supha Pharmachem's highest PS Ratio was 61.39. The lowest was 0.03. And the median was 0.27.
BOM:539561's PS Ratio is ranked better than 99.27% of 953
companies
in the Drug Manufacturers industry
Industry Median: 2.35
vs BOM:539561: 0.04
Supha Pharmachem Ltd revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Supha Pharmachem was -85.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -7.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 180.80% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 132.10% per year.
During the past 11 years, Supha Pharmachem's highest 3-Year average Revenue per Share Growth Rate was 1328.20% per year. The lowest was -64.70% per year. And the median was 142.45% per year.
Supha Pharmachem (BOM:539561) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Supha Pharmachem PS Ratio Related Terms
Supha Pharmachem PS Ratio Historical Data
* Premium members only.
The historical data trend for Supha Pharmachem's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Supha Pharmachem's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supha Pharmachem PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supha Pharmachem's PS Ratio distribution charts can be found below:
* The bar in red indicates where Supha Pharmachem's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Supha Pharmachem's Share Price of today is ₹0.33. Supha Pharmachem's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8.33.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Supha Pharmachem (BOM:539561) has a PS Ratio of 0.04 as of Aug. 10, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Supha Pharmachem and its competitors. This is 85% below median its historical median of 0.27. Over the past decade, Supha Pharmachem's PS Ratio has ranged from 0.03 to 61.39. According to the industry distribution chart, Supha Pharmachem ranks #7 out of 953 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is Supha Pharmachem's PS Ratio too high?
Supha Pharmachem's current PS Ratio of 0.04 is 85% below median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 61.39. The Drug Manufacturers industry median PS Ratio is 2.35. Supha Pharmachem's value of 0.04 is 98.3% below this industry median. Based on the distribution chart, Supha Pharmachem ranks #7 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Supha Pharmachem has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Supha Pharmachem's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Supha Pharmachem ranks #7 out of 953 companies for PS Ratio. This places Supha Pharmachem in the top 1% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.35. Supha Pharmachem's value of 0.04 is 98.3% below this benchmark. Historically, Supha Pharmachem's own PS Ratio has ranged from 0.03 to 61.39 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 2.35, Supha Pharmachem has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.35, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supha Pharmachem's current PS Ratio of 0.04 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Supha Pharmachem and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supha Pharmachem's current PS Ratio is 0.04, which is 85% below median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supha Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Supha Pharmachem (BOM:539561) is currently considered Possible Value Trap. The stock's GF Value™ is ₹1.52, compared to a current price of ₹0.33 — trading 78.3% below its estimated fair value. The current PS Ratio is 0.04, which is 85% below median its 10-year median of 0.27 and 98.3% below the Drug Manufacturers industry median of 2.35. Supha Pharmachem's overall GF Score™ is 56/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Supha Pharmachem (BOM:539561), the current PS Ratio is 0.04 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supha Pharmachem (BOM:539561) Overvalued in 2026?
Based on GuruFocus' analysis, Supha Pharmachem stock appears to be undervalued.
The current stock price of ₹0.33 is trading 78.3% below its estimated GF Value™ of ₹1.52.
GuruFocus considers Supha Pharmachem to be Possible Value Trap.
Key valuation signals for BOM:539561:
PS Ratio: 0.04 (85% below median its 10-year median of 0.27)
GF Value™: ₹1.52 vs. price of ₹0.33 (78.3% below fair value)
Industry Position: 98.3% below the Drug Manufacturers median (#7 of 953)
No single metric tells the full story. See the BOM:539561 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supha Pharmachem Ltd, formerly known as Remedium Lifecare Ltd, is engaged in the business of trading in API Intermediates (KSMs & CRMs) and various other raw materials used in API trading viz. Iso propyl Alcohol (IPA), Cyclohexane, DI Iso Propyl Amine (DIPA), Ethyl Acetate, Hydrazine Hydrate, Iso propyl Alcohol (IPA), Methylene Di Chloride, Potassium Carbonate Powder, Sodium Bi-Carbonate, Potassium Hydroxide Flakes, Sodium Chloride (Common Salt), Sodium Carbonate (SODA ASH), Amino isophthalic Acid, Tellurium(IV) Oxide, Grignard Reagent, Iodine, Selenium Metal Powder, Trimethyl Sulfoxonium Iodide (TMSI).
56GF Score
Get the complete analysis for BOM:539561
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539561 has been successfully added to your 
